CN109071521A - 作为fgfr抑制剂的杂环化合物 - Google Patents

作为fgfr抑制剂的杂环化合物 Download PDF

Info

Publication number
CN109071521A
CN109071521A CN201780006295.5A CN201780006295A CN109071521A CN 109071521 A CN109071521 A CN 109071521A CN 201780006295 A CN201780006295 A CN 201780006295A CN 109071521 A CN109071521 A CN 109071521A
Authority
CN
China
Prior art keywords
alkyl
compound
hydrogen
group
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780006295.5A
Other languages
English (en)
Other versions
CN109071521B (zh
Inventor
张汉承
刘世峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Innogate Pharma Co Ltd
Original Assignee
Hangzhou Innogate Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Innogate Pharma Co Ltd filed Critical Hangzhou Innogate Pharma Co Ltd
Publication of CN109071521A publication Critical patent/CN109071521A/zh
Application granted granted Critical
Publication of CN109071521B publication Critical patent/CN109071521B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Abstract

本发明提供了一种作为FGFR(成纤维细胞生长因子受体)抑制剂的杂环化合物。具体地，本发明提供了一种如下式(I)所示的化合物，包括可能存在的异构体(对映异构体或非对映异构体)、或其药学上可接受的盐、前药、氘代衍生物、水合物、溶剂合物。式(I)中各基团的定义如说明书中所述。本发明的化合物具有FGFR抑制活性，可以用于预防或治疗与FGFR活性或表达量相关的疾病。

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN201780006295.5A 2016-01-08 2017-01-09 作为fgfr抑制剂的杂环化合物 Active CN109071521B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610015536 2016-01-08
CN201610015536X 2016-01-08
PCT/CN2017/070674 WO2017118438A1 (zh) 2016-01-08 2017-01-09 作为fgfr抑制剂的杂环化合物

Publications (2)

Publication Number Publication Date
CN109071521A true CN109071521A (zh) 2018-12-21
CN109071521B CN109071521B (zh) 2019-10-25

Family

ID=59273958

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780006295.5A Active CN109071521B (zh) 2016-01-08 2017-01-09 作为fgfr抑制剂的杂环化合物

Country Status (3)

Country Link
US (1) US10934311B2 (zh)
CN (1) CN109071521B (zh)
WO (1) WO2017118438A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6854496B2 (ja) * 2016-12-12 2021-04-07 ハンジョウ イノゲート ファーマ カンパニー リミテッドHangzhou Innogate Pharma Co., Ltd. 三環式ヘテロアリール基含有化合物
US20220153766A1 (en) * 2019-03-15 2022-05-19 Hangzhou Innogate Pharma Co., Ltd. Condensed tricyclic compound used as kinase inhibitor
CN113583026A (zh) * 2020-04-30 2021-11-02 杭州英创医药科技有限公司 一类含有稠合三环结构的化合物
CN117736198A (zh) * 2022-09-21 2024-03-22 科辉智药生物科技(深圳)有限公司 大环含氮冠醚化合物及其作为蛋白激酶抑制剂的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101336237A (zh) * 2005-12-21 2008-12-31 诺瓦提斯公司 作为fgf抑制剂的嘧啶基芳基脲衍生物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20160679A1 (es) * 2013-10-18 2016-08-04 Eisai Randd Man Co Ltd Inhibidores de pirimidina del fgfr4

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101336237A (zh) * 2005-12-21 2008-12-31 诺瓦提斯公司 作为fgf抑制剂的嘧啶基芳基脲衍生物

Also Published As

Publication number Publication date
US20190100531A1 (en) 2019-04-04
WO2017118438A1 (zh) 2017-07-13
US10934311B2 (en) 2021-03-02
CN109071521B (zh) 2019-10-25

Similar Documents

Publication Publication Date Title
EP3184521B1 (en) Indazole compounds as fgfr kinase inhibitors, preparation and use thereof
US6413971B1 (en) Fused bicyclic pyrimidine derivatives
CN104024233B (zh) 通过fgfr激酶的抑制抗癌的苯并吡嗪类化合物
CN110582483A (zh) 含邻氨基杂芳环炔基的化合物及其制备方法和用途
KR102211310B1 (ko) [1,2,4]트라이아졸[4,3-에이]피리딘 유도체, 그의 제조 방법 또는 그의 의학적 용도
CN109071521B (zh) 作为fgfr抑制剂的杂环化合物
CN103261167A (zh) 取代的6，6-稠合含氮杂环化合物及其用途
WO2013170770A1 (zh) 具有抗肿瘤活性的乙炔衍生物
CN104926788B (zh) 取代哌啶类衍生物、含其的药物组合物及其在抗肿瘤中的应用
CA3032921A1 (en) Heterocyclic compounds as fgfr inhibitors
CN110028507B (zh) 具有trk激酶抑制活性化合物、制备方法、组合物及用途
WO2016173557A1 (zh) 一类具有激酶抑制活性的化合物、制备方法和用途
KR20190140966A (ko) 페닐-2-히드록시-아세틸아미노-2-메틸-페닐 화합물
CN113248521A (zh) 一种k-ras g12c抑制剂及其制备方法和应用
CN113387962A (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
JP2021501215A (ja) アミノ置換窒素含有縮合環化合物、その調製方法及び使用
CN105732615A (zh) Cdk激酶抑制剂
JP2020023441A (ja) Ｅｇｆｒ阻害及び腫瘍治療に有用な新規化合物
CN104822658B (zh) 作为多种激酶抑制剂的稠合三环酰胺类化合物
CN107383019B (zh) 吡唑并[4,3-h]喹唑啉类化合物及其用途
CN105164138A (zh) 新吗啉基蒽环类抗生素衍生物
CN116514846A (zh) 杂环类衍生物、其制备方法及其医药上的用途
AU2021341879A1 (en) Heterocyclic compounds as CBP/EP300 bromodomain inhibitors
KR102325163B1 (ko) 화합물의 제조 방법
WO2017049711A1 (zh) 喹啉类衍生物、其药物组合物、制备方法及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant